US2020023001A1PendingUtilityA1
GlycoFix (Structurally And Functionally Repaired Endothelial Glycocalyx)
Est. expiryJul 20, 2038(~11.9 yrs left)· nominal 20-yr term from priority
A61L 2300/45A61L 2300/236A61L 2300/22A61L 31/16A61L 29/16A61L 27/54A61L 27/507A61P 9/10A61K 31/661A61K 31/737A61K 9/0024
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are compositions comprising heparan sulfate, or a pharmaceutically acceptable salt thereof, and sphingosine-1-phosphate, or a pharmaceutically acceptable salt thereof. Such compositions are useful in a variety of methods, including methods of regenerating endothelial glycocalyx, preventing endothelial glycocalyx degradation and treating vascular disease.
Claims
exact text as granted — not AI-modified1 . A composition, comprising heparan sulfate, or a pharmaceutically acceptable salt thereof, and sphingosine-1-phosphate, or a pharmaceutically acceptable salt thereof.
2 . The composition of claim 1 , wherein the heparan sulfate is exogenous heparan sulfate.
3 . The composition of claim 2 , wherein the heparan sulfate is porcine mucosal heparan sulfate with an average molecular weight of about 15 kDa.
4 . A method of regenerating glycocalyx of a cell, comprising contacting the cell with an effective amount of heparan sulfate, or a pharmaceutically acceptable salt thereof, and an effective amount of sphingosine-1-phosphate, or a pharmaceutically acceptable salt thereof.
5 - 9 . (canceled)
10 . The method of claim 4 , wherein the cell is an endothelial cell.
11 . A method of treating a vascular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of heparan sulfate, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of sphingosine-1-phosphate, or a pharmaceutically acceptable salt thereof.
12 . The method of claim 11 , wherein the vascular disease is atherosclerosis, a blood clot, a stroke, peripheral artery disease, an aneurysm, a pulmonary embolism, carotid artery disease, arteriovenous malformation, critical limb ischemia, deep vein thrombosis, chronic venous insufficiency, a varicose vein, coronary artery disease, Raynaud's disease or vasculitis.
13 . The method of claim 12 , wherein the vascular disease is atherosclerosis.
14 . The method of claim 4 , wherein the heparan sulfate is exogenous heparan sulfate.
15 . The method of claim 14 , wherein the heparan sulfate is porcine mucosal heparan sulfate with an average molecular weight of about 15 kDa.
16 . An implant, comprising the composition of claim 1 .
17 . The implant of claim 16 , wherein the implant is a stent or catheter.
18 . The implant of claim 16 , wherein the heparan sulfate, or a pharmaceutically acceptable salt thereof, and the sphingosine-1-phosphate, or a pharmaceutically acceptable salt thereof, are coated on a surface of the implant.
19 . The implant of claim 16 , wherein the heparan sulfate is porcine mucosal heparan sulfate with an average molecular weight of about 15 kDa.
20 . A vascular graft, comprising the composition of claim 1 .
21 . The vascular graft of claim 20 , wherein the heparan sulfate is porcine mucosal heparan sulfate with an average molecular weight of about 15 kDa.
22 - 24 . (canceled)Join the waitlist — get patent alerts
Track US2020023001A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.